The behavioral and convulsant effects of pefloxacin (PEFLO), a quinolone derivative, were studied after intraperitoneal (i.p.) administration to Dilute Brown Agouti DBA/2J (DBA/2) mice, a strain genetically susceptible to sound-induced seizures. The anticonvulsant effects of some excitatory amino acid (EAA) antagonists acting at N-methyl-D-aspartate (NMDA) or ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate (KA) receptors and of some compounds enhancing ␥-aminobutyric acid (GABA)-ergic transmission against seizures induced by PEFLO were also evaluated. The present study demonstrated that both groups of compounds administered i.p. or intracerebroventricularly were able to protect against seizures induced by PEFLO. However, ifenprodil and (؎)-␣-(chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol (SL 82.0715), two compounds acting on the polyamine site of the NMDA receptor complex, were unable to provide any protection. The relationship between the different sites of action and the anticonvulsant activities of these derivatives were discussed. Although the main mechanism of PEFLO-induced seizures cannot be easily determined, potential interactions with the receptors of EAA exist. In fact, antagonists of EAA, and in particular, those acting at NMDA receptors, were able to increase the threshold for the seizures or to prevent the seizures induced by PEFLO, while compounds acting at the polyamine site did not provide any protection. The AMPA-KA receptor antagonists were also able to exert anticonvulsant activity, but with minor potency in comparison to those of NMDA antagonists. In addition, the fact that compounds enhancing GABA-ergic neurotransmission were also able to protect the mice against seizures induced by PEFLO suggests an involvement of GABA system.
Because of their excellent antibacterial activities, quinolone agents have been widely adopted for use in clinical practice. In particular, pefloxacin (PEFLO) shows a very broad spectrum of activity against gram-positive and gram-negative bacteria and is widely distributed in tissues. This explains why PEFLO is successful against various systemic infections. Although recently developed quinolones are less toxic than earlier compounds, they still produce a very few incidences of various adverse effects on the central nervous system such as dizziness, headache, seizures, and hallucinations (2, 17, 20, 25, 26) . We have previously reported the proconvulsant effects of several quinolones when administered together with aminophylline in rats and with ␤-lactam derivatives in mice (9) (10) (11) (12) . The convulsant actions of quinolones have been attributed to the inhibition of ␥-aminobutyric acid (GABA) binding to its receptor (1, 31, 39, 41) . However, the concentrations of quinolones able to interact with the GABA system are rather high and varied among the different quinolones tested by a factor of about 100. Thus, it appears questionable whether a specific interaction of quinolones with GABA receptors alone can explain the convulsant activities of these compounds (16) . In addition, some in vivo studies indicated that dopamine, opioid, and glutamergic receptors may also be involved in the effects of quinolones on the central nervous system (16, 42) . Because quinolones possess some chemical similarities to kynurenic acids, which may be endogenous ligands for excitatory amino acid (EAA) receptors (35), we may suppose a possible interaction of quinolones with glutamate receptor binding sites.
The genetically epilepsy-prone mouse, or the Dilute Brown Agouti DBA/2J (DBA/2) mouse, has been known since 1947 to be a strain of mice susceptible to audiogenic seizures (21) . In fact, mice of this strain undergo an age-dependent (between 16 and 30 days) sequence of generalized convulsions when they are exposed to a loud mixed-frequency sound (12 to 16 kHz; 90 to 120 dB) such as a doorbell (4, 6) . The audiogenic seizures in DBA/2 mice is a genetic form of reflex epilepsy; the counterpart in humans may be brain stem or centrencephalic epilepsy, e.g., "absence" or "musicogenic" seizures (4-6, 19, 33) . In addition, it has been reported that DBA/2 mice develop resistance to sound-induced seizures with maturity but still have increased susceptibility to seizures resulting from a variety of nonaudiogenic convulsant treatments including chemical and physical stimuli (4, 5, 19) . This change in seizure incidence with age is one of the more striking similarities between the human and the mouse forms of epilepsy. Thus, DBA/2 mice have been considered an excellent animal model for the study of certain kinds of human epilepsy and for testing convulsant or anticonvulsant drugs (4, 5, 7) . In fact, we have previously demonstrated that the convulsant properties of antibiotics and chemotherapies can be more easily evaluated with this model than with models with other strains of mice (9, 12, 14) . This mouse model was chosen for the examination of the effects of PEFLO since it might mirror PEFLO treatment of patients with predisposing epileptic factors. In previous studies we evaluated the proconvulsant effects of some quinolones on seizures induced by imipenem and cefazolin administration to DBA/2 mice and found that PEFLO was the most potent of the quinolones tested (9, 12) . Thus, with these concepts in mind, in this experimental study we used PEFLO to treat DBA/2 mice with the intention of gaining information on the possible interference of EAA antagonists and of drugs enhancing GABA-ergic transmission with the mechanisms responsible for PEFLO-induced seizures.
MATERIALS AND METHODS
Subjects. DBA/2 mice (weight, 16 to 24 g; age, 42 to 48 days) were purchased from Charles River (Calco, Como, Italy). Upon arrival at the laboratory, they were housed at 10 mice per cage in a controlled environment (temperature, 22 Ϯ 1ЊC; light-dark cycle, lights on from 0800 to 2000 h), with food and water available ad libitum.
Testing of anticonvulsant activity. We administered PEFLO and anticonvulsant compounds intraperitoneally (i.p.) in a volume of 0.1 ml/10 g of body weight; however, some compounds that do not cross the blood-brain barrier were administered intracerebroventricularly (i.c.v.) under ethyl ether anesthesia in a volume of 5 l/mouse by the method of De Sarro et al. (13) . Briefly, for i.c.v. administration, the injection needle of a Hamilton type 75N syringe fitted with a nylon stop to attain a depth of 3.2 mm was placed perpendicular to the surface of the skull. The coordinates for microinjections were as follows: 1.0 mm lateral from the midline and 1.5 mm posterior from the bregma. Eight to 10 animals were given each dose of the compound being tested. The mice were divided into four groups, as follows: Group 1 consisted of mice injected i.p. with several doses of PEFLO (0.1 to 1.0 mg/g of body weight given i.p.). Group 2 consisted of animals that were pretreated i.p. with several doses of both EAA receptor antagonists and drugs enhancing GABA-ergic transmission and that were then injected with a stated dose of PEFLO (0.78 mg/g, which approximates the i.p. 95% convulsant dose [CD 95 ] for clonus). Group 3 consisted of animals that were pretreated i.c.v. with several doses of both receptor antagonists of EAAs and drugs enhancing GABA-ergic transmission and that were injected i.p. with a stated dose of PEFLO (0.78 mg/g, which approximates the i.p. CD 95 for clonus). Group 4 consisted of animals that were pretreated i.p. with a single dose of MK-801, CPPene, CGP 39551, NBQX, 2,3-BZ-2, DIA, and GVG or vehicle at appropriate times before the injection of different doses of PEFLO (0.2 to 2.0 mg/g given i.p.) (see Tables 1 and 2 for definitions of the abbreviations).
After the administration of PEFLO the mice were observed for 120 min through a Plexiglass box Tables 1 and 2 . Figures 1, 2 , and 3 show the sites of action of the different compounds tested. Administration of compounds. The compounds were prepared at an appropriate concentration. The compounds administered i.p., PEFLO (pefloxacin mesylate; Rhone-Pulenc Labs, Milan, Italy), CCP, CPPene, MK-801, CGP 39551, IFE, SL 82.0715, NBQX, GVG, BAC, TIA, and DIA, were dissolved in sterile saline. GYKI 52466 and 2,3-BZ-2 were also administered i.p. but were dissolved in 50% dimethyl sulfoxide and 50% sterile saline.
The compounds administered i.c.v., CPPene, MK 801, NBQX, AP7, KYNA, CNQX, ␥-D-GAMS, and MSC, were dissolved in a minimum quantity of 1 N NaOH, and the final volume was made up with sodium phosphate buffer (67 mM). When necessary the pH was adjusted to 7.3 to 7.4 by adding 0.2 N HCl.
Electrocortical activity. Electrocortical activity was recorded (eight-channel electrocorticograph machine; OTE Biomedica, Florence, Italy) through four chronically implanted steel-screw electrodes inserted bilaterally onto the frontoparietal area. At least three mice, treated with CCPene, MK-801, DIA, GVG, or 2,3-BZ-2-PEFLO (0.78 mg/g given i.p.) were studied to evaluate changes in ECoG activity.
Statistical analysis. Statistical comparisons between control (vehicle Ϫ PEFLO) and drug-treated groups were made by using Fisher's exact probability test (incidence of the seizure phases). The percent incidence of each phase of the seizure was determined for each dose of PEFLO administered. CD 50 s with 95% confidence limits for each phase of the seizure response were estimated by the method of Litchfield and Wilcoxon (24) adapted for analysis with an International Business Machines computer. The CD 95 of PEFLO by i.p. administration was also evaluated by the same method (24) . The CD 95 of PEFLO was used to assess the possible anticonvulsant effects shown by the several compounds tested. The lethality following PEFLO-induced seizures was scored within 120 min, and 50% lethal doses (LD 50 s) were calculated by the same method (24) . The 50% effective doses (ED 50 s), which were the doses of the compounds tested that were able to suppress seizures in 50% of the animals treated with PEFLO, were also estimated by the method of Litchfield and Wilcoxon (24) .
RESULTS
Effects of systemic administration of PEFLO. Systemic (i.p.) administration of PEFLO (0.1 to 1.0 mg/g) consistently resulted in clonic-tonic seizures which appeared within 14 to 20 min following the administration of the drug to the mice and which lasted from 25 to 90 min, depending on the dose. After administration of the lowest doses of PEFLO, mice showed an increase in locomotor activity, rare episodes of wild running or escape response, nodding, and clonus of the forelimbs and hind limbs. With higher doses (0.6 and 0.8 mg/g) tonus of the forelimbs and hind limbs was also observed, and in some animals the tonic extension of the hind limbs was followed by respiratory arrest and death (Table 3 ). The CD 50 of PEFLO for producing clonus was 0.35 mg/g (0.26 to 0.47 mg/g), while that for triggering tonus was 0.44 mg/g (0.34 to 0.56 mg/g) ( a Male DBA/2 mice were randomly assigned to experimental groups, each containing 10 animals, and were injected i.p. with various doses of PEFLO. The data are presented as the number of animals showing seizure phases among the 10 mice tested. and 8 nmol/g, respectively), NBQX (10, 20, and 30 g/g, equivalent to 29.2, 58.4, and 87.7 nmol/g, respectively), GYKI 52466 (10, 20, and 30 g/g, equivalent to 33, 66, and 100 nmol/g, respectively), 2,3-BZ-2 (10, 20, and 30 g/g, equivalent to 34, 67, and 101 nmol/g, respectively), IFE (0.6, 0.8, and 1.0 g/g, equivalent to 1.5, 2, and 2.5 nmol/g, respectively), SL 82.0715 (0.6, 0.8, and 1.0 g/g, equivalent to 1.6, 2.1, and 2.6 nmol/g, respectively), at different times (Table 1) before the administration of a single dose of PEFLO (0.78 mg/g; approximately the CD 95 ) was able to prevent the clonic and/or tonic components of PEFLO-induced convulsions (Table 5) . At the doses used, IFE and SL 82.0715, however, were unable to protect against the tonic and clonic components of PEFLO-induced seizures. Following the systemic administration of EAA antagonists, the order of the potencies of the antagonists in protecting the mice against PEFLO-induced convulsions were as follows: MK-801 Ͼ CGP 39551 Ͼ CPPene Ͼ CPP Ͼ GYKI 52466 Ͼ NBQX Ͼ 2,3-BZ-2 (Table 5 ). In addition, pretreatment with CGP 39551 (2 g/g, equivalent to 8 nmol/g), MK-801 (0.3 g/g, equivalent to 0.75 nmol/g), NBQX (30 g/g, equivalent to 87.7 nmol/g), 2,3-BZ-2 (30 g/g, equivalent to 101 nmol/g), and CPPene (8 g/g, equivalent to 30 nmol/g) was able to increase the threshold for seizures induced by different doses of PEFLO given i.p. (Fig. 4 and Table 4 ). The highest doses of all compounds studied, with the exception of IFE (1 g/g, equivalent to 2.5 nmol/g) and SL 82.0715 (1 g/g, equivalent to 2.6 nmol/g), were able to significantly reduce the incidence of the wild running phase.
Effects of systemic administration of compounds enhancing GABA-ergic neurotransmission on seizures induced by PEFLO. i.p. pretreatment with DIA (0.5, 1, and 2 g/g, equivalent to 1.76, 3.51, and 7 nmol/g, respectively), TIA (1, 2, and 4 g/g, equivalent to 2.4, 4.8 and 9.7 nmol/g, respectively), and GVG (1,250, 1,500, and 2,000 g/g, equivalent to 9.7, 11.6, and 15.5 mol/g, respectively) at different times (Table 2 ) before PEFLO administration (0.78 mg/g given i.p.; approximately the CD 95 ) was able to significantly reduce the occurrence of seizures induced by PEFLO. Whereas BAC at the lowest dose (2.5 g/g, equivalent to 11.7 nmol/g) was unable to significantly reduce the tonic and clonic components of PEFLO-induced seizures, the largest doses of BAC (5, 10, and 20 g/g, equivalent to 32.4, 46.8, and 93.6 nmol/g, respectively) significantly antagonized both the clonic and tonic seizures, but some animals lost the righting reflex ( Table 5 ). The order of the potencies of the compounds described above in protecting against PEFLO-induced convulsions was DIA Ͼ TIA Ͼ BAC Ͼ GVG (Table 5 ). In addition, pretreatment with GVG (1,500 g/g, equivalent to 11.6 mol/g) and DIA (2 g/g, equivalent to 7 nmol/g) was able to increase the threshold for seizures induced by PEFLO (Fig. 4 and Table 4) . (Table 6) .
Electrocortical activity. In the animals used to study electrocortical activity, we observed that the electrocorticographic epileptic discharges appeared within 12 to 20 min in mice pretreated i.p. with vehicle-PEFLO (0.78 mg/g). Epileptic dis- (24) . b Significant differences (P Ͻ 0.05) between CD 50 s for groups treated with vehicle-PEFLO and groups treated with EAA antagonists-PEFLO and DIA-or GVG-PEFLO are denoted. charges did not appear in animals pretreated with CPPene (8 g/g given i.p)-PEFLO or DIA (1 g/g given i.p.)-PEFLO or were less evident in those animals pretreated with MK-801 (0.3 g/g given i.p.)-PEFLO, 2,3-BZ-2 (20 g/g given i.p.)-PEFLO, or GVG (1.5 mg/g given i.p.)-PEFLO (Fig. 5, 6 , and 7).
DISCUSSION
The mechanisms of the convulsant activities of quinolones are largely unresolved, despite suggestions from in vitro data that quinolones may be acting through inhibition of GABA binding to its receptor sites (1, 31, 39, 41) . In particular, since the epileptogenic activities of some quinolones were suppressed by compounds that enhance GABA-ergic neurotransmission, i.e., GVG and TIA, or by MSC and DIA, which are agonists for the GABA A -benzodiazepine receptor complex (22) , while it was influenced at neurotoxic doses by baclofen, a GABA B receptor agonist, the epileptogenic activities of quinolones likely involve the GABA A -benzodiazepine receptor complex. This conclusion is in agreement with the results of previous studies on the interaction of quinolones with the benzodiazepine-GABA receptor complex (1, 31, 39, 41) . In addition, Enginar and Eroglu (18) demonstrated that the quinolone ofloxacin is able to reduce the threshold of convulsions induced by pentylentetrazole, which is believed to block the actions of GABA through its effects at the chloride ionophore coupled to the GABA A receptor complex, and therefore, it has been considered a specific DIA antagonist (29, 36, 37) . Concerning the anticonvulsant potencies of the different compounds tested, differences exist among the groups. PEFLO with potencies higher than or equal to those of the GABA A agonist MSC, the benzodiazepine DIA, and the inhibitor of GABA uptake TIA. ␥-D-GAMS, GYKI 52466, 2,3-BZ-2, and NBQX, which are preferential ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate (KA) receptor antagonists (8, 14, 23, 34) , also antagonized the seizures induced by PEFLO, but with minor potencies compared with those of the NMDA antagonists. The doses of AMPA-KA antagonists used are in the range of those which have been shown to block excitatory neurotransmission at non-NMDA receptors, thus demonstrating that AMPA-KA-dependent mechanisms are activated in the course of PEFLO-induced seizures as well. The broad-spectrum antagonist KYNA was also found to be a potent anticonvulsant, and a trend similar to that seen for KYNA was seen following the systemic administration of some selective NMDA receptor antagonists. It is remarkable that the doses of MK-801, CPPene, CGP 39551, and CPP required to block the clonic and tonic components of PEFLO-induced convulsions were less than or similar to those used in other experimental models to antagonize clonic-tonic seizures in mice (27, 38) , while the doses of drugs enhancing GABA-ergic transmission are usually higher than those able to block audiogenic seizures in DBA/2 mice (4-6). IFE and SL 82.0715, two compounds that act on the polyamine site of the NMDA receptor complex (3, 30) , were unable to protect against seizures induced by PEFLO, suggesting that the polyamine site does not play a principal role in the genesis of seizures induced by PEFLO. The results of this study demonstrate that the excitation mediated by dicarboxylic amino acids plays a crucial role in the pathogenesis of seizures caused by PEFLO in mice, similar to that observed following pretreatment with EAA antagonists in seizures induced by bicuculline, pilocarpine, and imipenem (14, 15, 28, 40) . It is most likely that excessive activation of EAA receptors occurs secondarily to or concomitantly with the impairment of the inhibitory GABAergic neurotransmission caused by PEFLO and is essential for the propagation of seizures. The NMDA receptors seem to play a particularly pivotal role in PEFLO-induced seizures, since NMDA antagonists were potent anticonvulsants in the present study. This observation is in line with those from a previous study showing that the proconvulsive activities of some quinolones may be antagonized by EAA antagonists (42) . The present study also demonstrated that the seizure intensity was consistently reduced in animals pretreated with most EAA antagonists or the latter phases of seizures failed to occur. In addition, a different incidence of seizures was observed in mice after pretreatment with EAA antagonists. A quantitative comparison of the anticonvulsant efficacies of the EAAs in antagonizing PEFLO-induced seizures and audiogenic seizures in DBA/2 mice seems to demonstrate some similarities among the EAAs (e.g., the anticonvulsant potencies of CPP, CPPene, CGP 39551, and NBQX). However, IFE and SL 82.0715 showed no or weak anticonvulsant activity or less of a protective effect against PEFLO-induced seizures, while they were potent anticonvulsants against audiogenic seizures (3). The possibility that PEFLO possesses agonistic or modulatory properties at receptors activated by EAAs might be an alternative explanation to the one involving GABA-ergic transmission, which requires experimental confirmation. Since previous studies have indicated that systemic administration of quinolones to experimental animals or humans may sometimes produce proconvulsant or epileptogenic effects (9-12, 17, 18, 20, 25, 32, 42) , we conclude that physicians should consider the possible epileptogenic activity of PEFLO when treating patients with predisposing epileptic factors.
